Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA-AF ACS trial
jRCTs051260077Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of clopidogrel, prasugrel and Draxaban in Atrial fibrillation (AFib), acute coronary syndrome (ACS) and coronary arteriosclerosis (2 arms), sponsored by Japan Agency for Medical Research and Development. Started Oct 2026; status: recruiting.
02
Drugs
clopidogrelprasugrelDraxaban
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on jRCTs051260077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260077.